Atara Biotherapeutics, Inc.
ATRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $99,665 | $54,312 | $334,527 | $1,476,239 |
| - Cash | $25,030 | $25,841 | $92,942 | $106,084 |
| + Debt | $43,831 | $57,872 | $71,704 | $28,271 |
| Enterprise Value | $118,466 | $86,343 | $313,289 | $1,398,426 |
| Revenue | $128,940 | $8,573 | $63,573 | $20,340 |
| % Growth | 1,404% | -86.5% | 212.6% | – |
| Gross Profit | $107,931 | -$313 | $63,573 | -$261,661 |
| % Margin | 83.7% | -3.7% | 100% | -1,286.4% |
| EBITDA | -$75,749 | -$265,997 | -$222,264 | -$331,117 |
| % Margin | -58.7% | -3,102.7% | -349.6% | -1,627.9% |
| Net Income | -$85,403 | -$276,126 | -$228,302 | -$340,141 |
| % Margin | -66.2% | -3,220.9% | -359.1% | -1,672.3% |
| EPS Diluted | -11.41 | -65.18 | -55.96 | -90.78 |
| % Growth | 82.5% | -16.5% | 38.4% | – |
| Operating Cash Flow | -$68,717 | -$192,977 | -$270,430 | -$220,522 |
| Capital Expenditures | -$246 | -$1,223 | -$4,193 | -$10,580 |
| Free Cash Flow | -$68,963 | -$194,200 | -$274,623 | -$231,102 |